Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose,Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Felbinac (Primary)
- Indications Inflammation; Pain
- Focus Adverse reactions; First in man
- Sponsors Shijiazhuang Yiling Pharmaceutical
- 22 Jul 2020 Results assessing pharmacokinetics, safety and tolerability of intravenous Felbinac Trometamol in healthy chinese volunteers from two clinical studies: CTR20170496 and CTR20180896 published in the CNS Drugs
- 01 Jul 2020 Status changed from recruiting to completed.
- 13 Aug 2018 New trial record